Boundless Bio, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
BOLD$2.45-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss | $(45,312) | $(48,915) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 4,793 | 5,508 |
| Depreciation and amortization | 944 | 790 |
| Accretion of investments, net | (2,085) | (4,003) |
| Non-cash lease expense | 2,475 | 1,894 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (237) | (1,299) |
| Accounts payable and accrued liabilities | 657 | 2,821 |
| Operating lease liabilities | 2,211 | (2,074) |
| Net cash used in operating activities | (36,554) | (45,278) |
| Cash flows from investing activities | ||
| Purchases of investments | (135,792) | (161,029) |
| Maturities of investments | 160,744 | 135,175 |
| Purchases of property and equipment | (122) | (2,070) |
| Net cash provided by/ (used in) investing activities | 24,830 | (27,924) |
| Cash flows from financing activities | ||
| Proceeds from the issuance of common stock from initial public offering, net of discounts | — | 93,000 |
| Payments of common stock offering costs | — | (3,349) |
| Proceeds from the exercise of stock options | — | 59 |
| Proceeds from issuance of common stock under the Employee Stock Purchase Plan | 117 | — |
| Net cash provided by financing activities | 117 | 89,710 |
| Net increase/ (decrease) in cash, cash equivalents, and restricted cash | (11,607) | 16,508 |
| Cash, cash equivalents, and restricted cash at beginning of period | 27,147 | 24,266 |
| Cash, cash equivalents, and restricted cash at end of period | $15,540 | $40,774 |
| Components of cash, cash equivalents, and restricted cash | ||
| Cash and cash equivalents | $14,980 | $40,214 |
| Restricted cash | 560 | 560 |
| Cash, cash equivalents, and restricted cash at end of period | $15,540 | $40,774 |
| Non-cash investing and financing activities | ||
| Change in unpaid common stock issuance costs | $— | $(197) |
| Decrease to right-of-use assets due to remeasurement of lease obligation | $(84) | $— |
| Vesting of early exercised stock options | $— | $5 |
| Unpaid property and equipment purchases | $— | $106 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.